Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ingredient Tests Fail To Support Supplement Pain, Heart Claims – NAD

This article was originally published in The Tan Sheet

Executive Summary

Ads for the Institute for Vibrant Living’s Alleviate made express claims unsupported by ingredient studies, says the National Advertising Division in review promoted by the Council for Responsible Nutrition. The firm discontinued the claims.

You may also be interested in...



ACT Dry Mouth Claims Get Parched In Industry Self-Regulation Review

Sanofi and GSK appeal Council of Better Business Bureaus investigative arm's recommendations from review of  ACT Dry Mouth ad claims. GSK disagrees that Sanofi's could continue using a claim of "moisturizes dry mouth" and Sanofi disagrees that it did not substantiate claims that established ACT Dry Mouth, marketed with cavity prevention claims, as providing benefits similar to GSK's Biodene, which has pre-market approval for an indication of lubricating and coating the interior of the mouth and gums with moisture.

ACT Dry Mouth Claims Get Parched In Industry Self-Regulation Review

Biodene maker GSK challenged Sanofi's ACT Dry Mouth advertising and both companies find disappointments in the Better Business Bureaus' advertising division's review.

ACT Dry Mouth Claims Get Parched In Industry Self-Regulation Review

Biodene maker GSK challenged Sanofi's ACT Dry Mouth advertising and both companies find disappointments in the Better Business Bureaus' advertising division's review.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS107764

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel